Cellceutix Receives FDA Orphan Drug Designation for Kevetrin for the Treatment of Retinoblastoma
BEVERLY, MA--(Marketwired - November 23, 2015) - Cellceutix Corporation (OTC: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies with oncology, dermatology, anti-inflammatory and antibiotic …